Syntara (SNT) investor relations material

Strategic Outlook and Pipeline Progress

• Entering 2026 with a robust pipeline and five clinical trials expected to deliver efficacy and safety data within 12 months.

• Institutional backing stands at up to 47%, with over AUD 11.5 million in non-dilutive grant funding and a cash balance of AUD 12.3 million extending runway into 2027.

• Lead asset amsulostat presented at ASH, with ongoing studies in myelofibrosis and MDS recruiting and generating data.

• Regulatory engagement broadened to FDA and EMA, with orphan drug designation granted and positive EMA opinion in myelofibrosis.

• Experienced management team with a strong track record in licensing and capital raising.

Clinical Trial Milestones and Expectations

• Interim safety and efficacy data for AZALOX (high-risk MDS) expected mid-year; MESSAGE (low-risk MDS) data in the second half.

• Pancreatic cancer trial initiation set for the second half, fully grant-funded in collaboration with Garvan Institute.

• Skin scarring programs (SNT-6302, SNT-9465) to deliver interim and top-line data through the year, with SNT-9465 progressing to hypertrophic scar study.

• PXS-4728 in iRBD Parkinson's completed recruitment, with phase II data due in Q2 2026 and a $1.8m milestone payment in Q1 2026.

• Phase 2 initiation and top-line data readouts for key pipeline assets scheduled throughout 2026.

Asset Differentiation and Market Positioning

• Amsulostat's robust safety profile and unique mechanism allow use across disease stages and potential for combination therapies.

• Long patent life and unencumbered IP make amsulostat attractive for acquisition or licensing.

• Market may undervalue the asset's safety, rapid efficacy, and the normalcy of FDA's phase II requirement.

• Three Phase 2 studies in blood cancer with an addressable market over $4.5bn.

• Positive 52-week top-line data from Phase 2 blood cancer trial for amsulostat, showing favorable safety and durability.